Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CRHR1 | P34998 | 3/20 | 0.45 |
| ▸ | LMNA | P02545 | 1/20 | 0.35 |
| ▸ | GAA | P10253 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5842790 | 0.90 | CRHR1 (0.44) | CRHR1LMNAGAA | |
| SCHEMBL5843400 | 0.84 | CRHR1 (0.46) | CRHR1 | |
| SCHEMBL5843948 | 0.83 | CRHR1 (0.62) | CRHR1 | |
| SCHEMBL5843981 | 0.79 | CRHR1 (0.46) | CRHR1LMNAGAA | |
| SCHEMBL6303533 | 0.78 | CRHR1 (0.48) | CRHR1 | |
| SCHEMBL5842983 | 0.77 | CRHR1 (0.47) | CRHR1LMNAGAA | |
| SCHEMBL6428479 | 0.77 | CRHR1 (0.38) | CRHR1LMNAGAAALDH1A1 | |
| SCHEMBL5843895 | 0.76 | CRHR1 (0.46) | CRHR1LMNAGAAALDH1A1 | |
| SCHEMBL5844341 | 0.75 | CRHR1 (0.59) | CRHR1 | |
| SCHEMBL5843390 | 0.73 | CRHR1 (0.45) | CRHR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7125880-B1 | Corticotropin releasing factor antagonists | PFIZER INC. (US) | 2006-10-24 | — | — | US | disclosed |
| US-7067664-B1 | Corticotropin releasing factor antagonists | PFIZER INC. (US) | 2006-06-27 | — | — | US | disclosed |
| US-6956047-B1 | Corticotropin releasing factor antagonists | PFIZER INC. (US) | 2005-10-18 | — | — | US | disclosed |
| US-6875769-B2 | Substituted6,6-hetero-bicyclicderivatives | PFIZER INC. (US) | 2005-04-05 | — | — | US | disclosed |
| US-20050032846-A1 | Corticotropin releasing factor antagonists | PFIZER INC. | 2005-02-10 | — | — | US | disclosed |
| US-6844351-B1 | Corticotropin releasing factor antagonists | PFIZER INC. (US) | 2005-01-18 | — | — | US | disclosed |
| US-6833378-B2 | Pyridines, pyrimidines, purinones, pyrrolopyrimidinones and pyrrolopyridinones; useful in the treatment disorders including CNS and stress-related disorders. | PFIZER INC | 2004-12-21 | — | — | US | disclosed |
| EP-0925298-B1 | SUBSTITUTED 6,6-HETERO-BICYCLIC DERIVATIVES | PFIZER (US) | 2004-04-14 | — | — | EP | disclosed |
| US-20030114671-A1 | Substituted6,6-hetero-bicyclicderivatives | CHEN YUHPYNG L (US) | 2003-06-19 | — | — | US | disclosed |
| EP-0920429-B1 | SUBSTITUTED PYRIDO- OR PYRIMIDO-CONTAINING 6,6- OR 6,7-BICYCLIC DERIVATIVES | PFIZER (US) | 2003-02-19 | — | — | EP | disclosed |
| EP-1263732-A1 | CORTICOTROPIN RELEASING FACTOR ANTAGONISTS | Pfizer Products Inc. (US) | 2002-12-11 | — | — | EP | disclosed |
| US-6492520-B1 | COMPOUNDS (I) ARE CORTICOTROPIN RELEASING FACTOR (HORMONE) CRF (CRH) ANTAGONISTS. | PFIZER INC | 2002-12-10 | — | — | US | disclosed |
| US-20020016328-A1 | Corticotropin releasing factor antagonists | PFIZER INC. | 2002-02-07 | — | — | US | disclosed |
| WO-2001053263-A1 | CORTICOTROPIN RELEASING FACTOR ANTAGONISTS | PFIZER PRODUCTS INC. (US) | 2001-07-26 | — | — | WO | disclosed |
| EP-0925298-A1 | SUBSTITUTED 6,6-HETERO-BICYCLIC DERIVATIVES | PFIZER INC. (US) | 1999-06-30 | — | — | EP | disclosed |
| EP-0920429-A1 | SUBSTITUTED PYRIDO- OR PYRIMIDO-CONTAINING 6,6- OR 6,7-BICYCLIC DERIVATIVES | PFIZER INC. (US) | 1999-06-09 | — | — | EP | disclosed |
| WO-1998008846-A1 | SUBSTITUTED 6,6-HETERO-BICYCLIC DERIVATIVES | PFIZER INC. (US) | 1998-03-05 | — | — | WO | disclosed |
| WO-1998005661-A1 | SUBSTITUTED PYRIDO- OR PYRIMIDO-CONTAINING 6,6- OR 6,7-BICYCLIC DERIVATIVES | PFIZER INC. (US) | 1998-02-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020016328-A1 | Corticotropin releasing factor antagonists | CRH, CRHR2, CRHR1 | CRHR1 3/4885LMNA 4189/4885GAA 2029/4885 |
| US-20030114671-A1 | Substituted6,6-hetero-bicyclicderivatives | CYP2D6, CYP2B6, CYP2A6 | CRHR1 2119/4885LMNA 3247/4885GAA 1100/4885 |
| US-20050032846-A1 | Corticotropin releasing factor antagonists | CRH, CRHR2, CRHR1 | CRHR1 3/4885LMNA 4152/4885GAA 1321/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.